BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

Kimberly B. Dahlman; Junfeng Xia; Katherine E. Hutchinson; Charles Ng; Donald Hucks; Peilin Jia; Mohammad Atefi; Zengliu Su; Suzanne Branch; Pamela L. Lyle; Donna J. Hicks; Viviana Bozón; John A. Glaspy; Neal Rosen; David B. Solit; James L. Netterville; Cindy L. Vnencak‐Jones; Jeffrey A. Sosman; Antoni Ribas; Zhongming Zhao; William Pao

doi:10.1158/2159-8290.cd-12-0097

Abstract

This study shows that cells harboring BRAF(L597R) mutants are sensitive to MEK inhibitor treatment, providing a rationale for routine screening and therapy of BRAF(L597R)-mutant melanoma.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Dahlman et al. (2012) studied this question.

synapsesocial.com/papers/69d89ba3183921ebcaae2d49 https://doi.org/10.1158/2159-8290.cd-12-0097

View at Publisher

Ask AI

Bookmark

Share

BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

Abstract

Discussion

Cite This Study

BRAF L597 Mutations in Melanoma Are Associated with Sensitivity to MEK Inhibitors

Abstract

Discussion

Cite This Study

Keep reading

More related papers

More from Cancer Discovery

Keep reading

More related papers

More from Cancer Discovery